Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
에이피트바이오(주) logo — 항체기반 혁신 신약개발 전문 바이오텍입니다. 인간 Synthetic F...

에이피트바이오(주)

항체기반 혁신 신약개발 전문 바이오텍입니다. 인간 Synthetic Fab 라이브러리를 기반으로 높은 항원 결합능, 낮은 면역원성, 우수한 물성을 갖는 항체 발굴 및 신속한 항체 제작 서비스를 제공하고 있습니다.

Founded 2018 Korea South Korea South 1 employees Series A Total: $12.66M Biopharma, Biotechnology

General Information

Company Name 에이피트바이오(주)
Founded Year 2018
Location Korea South Korea South +1
Employees 1
Industries Biopharma, Biotechnology
Funding Stage Series A
Social

Get notified when 에이피트바이오(주) moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About 에이피트바이오(주)

APTBIO is a biotech startup based in South Korea specializing in innovative drug development based on antibody technology. The company has developed a platform for antibody-based drug development, including the production of human synthetic antibody (Fab) libraries, the discovery and optimization of monoclonal antibodies, the production of bispecific antibodies, and the development of antibodies, and ADC therapeutics. APTBIO is currently developing first-in-class monoclonal antibodies and bispecific and ADC therapeutics, with a pipeline of 6 proprietary projects. The company also offers antibody discovery and production services at a global level, leveraging the high antigen binding affinity, low immunogenicity, and excellent properties of antibodies based on the human synthetic Fab library. In February 2021, APTBIO secured a $12.66M Series A investment from UTC 2019 BioVentureFund, LSK Investment, Shinhan Venture Investment, Laguna Investment, KB Securities, Kolon Investment, and Hyundai Venture Investment Corporation. With its pioneering approach to drug development and strong investor backing, APTBIO is poised for significant growth and innovation within the Biopharma and Biotechnology industries.

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 7
Investor Investor Investor Investor Investor Investor Investor
08 Feb 2021

에이피트바이오(주) Alternatives & Competitors

에이피트바이오(주) vs
위올라잇
위올라잇 Korea South

상상, 생각, 사람을 담습니다. / 플랫폼 & 출판 비즈니스를 전개합니다.

1 employees
에이피트바이오(주) vs
LifeSemantics
LifeSemantics Korea South

디지털헬스 분야의 Leader 라이프시맨틱스는 세상의 헬스데이터를 통합하고, 디지털헬스의 표준을 제시합니...

Corporate Round
23 employees
Biotechnology, Cloud Infrastructure
에이피트바이오(주) vs
WELT corp
WELT corp Korea South

[Wellness Technology] 웰트는 개인화된 디지털 치료제와 웨어러블을 개발하는 스타트업입니다. 2016년 삼...

Series C
29 employees
Fashion, Hardware

FAQ About 에이피트바이오(주)

항체기반 혁신 신약개발 전문 바이오텍입니다. 인간 Synthetic Fab 라이브러리를 기반으로 높은 항원 결합능, 낮은 면역원성, 우수한 물성을 갖는 항체 발굴 및 신속한 항체 제작 서비스를 제공하고 있습니다.
에이피트바이오(주) was founded in 2018.
에이피트바이오(주) is headquartered in Korea South.
에이피트바이오(주) operates in the following industries: Biopharma, Biotechnology.
에이피트바이오(주) has approximately 1 employees.
에이피트바이오(주) has completed 1 funding round, raising a total of $12.66M. The latest funding stage is Series A.
Top alternatives and competitors to 에이피트바이오(주) include 위올라잇, LifeSemantics, WELT corp, Supercat Inc., LENDIT.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
에이피트바이오(주) and 위올라잇 are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors 에이피트바이오(주) and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy